HC seeks Pfizer reply on plea against patent to PC vaccine

Image
Press Trust of India New Delhi
Last Updated : Oct 13 2017 | 8:57 PM IST
A petition was today filed in the Delhi High Court challenging the patent granted to US pharmaceutical company Pfizer for pneumococcal conjugate vaccine (PCV) used to protect infants, young children and adults from pneumoniae bacteria.
The plea came up for a brief hearing before Justice Vibhu Bakhru and a notice was issued on the petition.
The court listed the matter for November 21 seeking response of the Centre, the Controller General of Patents, Assistant Controller of Patents and the US firm.
The petition by a representative of Mdecins Sans Frontires (MSF) or Doctors Without Borders - a Paris-based international humanitarian-aid organization - sought setting aside of an August 11 order of the Assistant Controller of Patents and Designs granting patent for the vaccine.
The association, represented by senior advocate Anand Grover, said the decision was without application of mind, improper, illegal and contrary to the principles of law.
The plea, filed through advocate Rajeshwari, said as pneumonia is the leading cause of childhood death, the vaccine is important for children in general and there is a need for this vaccine to be available at an affordable price.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 13 2017 | 8:57 PM IST

Next Story